Kymera Announces First Patient Dosed in Asthma Drug Trial
Kymera has begun dosing in BREADTH, a global, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in approximately 264...
Jon Napitupulu
FDA Clears Scancell’s Phase 3 Trial for Advanced Melanoma
Updated Phase 2 data show a 74% progression-free survival rate at 16 months in the target population for iSCIB1+...
Longeveron Gets FDA Meeting for Pivotal HLHS Phase 2 Trial
Longeveron plans a third-quarter 2026 top-line readout for ELPIS II, a 40-patient, 12-site pivotal Phase 2b trial of laromestrocel...
LB Pharma Begins Phase 2 Trial for Bipolar Depression Drug
LB Pharmaceuticals has initiated ILLUMINATE-1, a U.S.-only, six-week, outpatient Phase 2 trial of LB-102 in bipolar I depression, randomizing...
Breakthrough Aging Study Unlocks Peak Performance Secrets
A neuroimaging study in older adults reported measurable upregulation of cholinergic activity following a course of BrainHQ cognitive training,...
First Patient Dosed in Phase 3 Ibsrela Constipation Study
First patient dosed in ACCEL, a 700‑patient, 26‑week, randomized, double‑blind, placebo‑controlled Phase 3 trial assessing twice‑daily tenapanor (IBSRELA) in...
FDA Victory: Scancell’s Pioneering Melanoma Trial Cleared
Updated Phase 2 data point to a 74% progression-free survival rate at 16 months for iSCIB1+ added to ipilimumab...
FDA Lifts Clinical Hold, A Breakthrough for Intellia’s Trial
A Grade 4 spike in liver transaminases with increased total bilirubin that triggered FDA clinical holds in October 2025...
Belite Bio Finishes Enrollment for Tinlarebant STGD1 Trial
Belite Bio’s tinlarebant previously delivered a 36% reduction in lesion growth versus placebo (p=0.0033) in the pivotal Phase 3...
Briacell Trial Shows Remarkable Metastatic Cancer Survival
BriaCell reported a 52% one-year and 32% two-year survival rate in a Phase 2 cohort of heavily pretreated metastatic...